BriaCell Provides Update to its Board of Directors
BriaCell Therapeutics, a clinical-stage biotechnology company specializing in immunotherapies for cancer, has announced the resignation of Mr. Marc Lustig from its Board of Directors. The resignation is effective immediately. The company expressed gratitude for Mr. Lustig's significant contributions during his tenure.
BriaCell Therapeutics, un'azienda biotecnologica in fase clinica specializzata in immunoterapie per il cancro, ha annunciato le dimissioni del signor Marc Lustig dal suo Consiglio di Amministrazione. Le dimissioni sono efficaci immediatamente. L'azienda ha espresso gratitudine per i significativi contributi del signor Lustig durante il suo mandato.
BriaCell Therapeutics, una empresa biotecnológica en etapa clínica especializada en inmunoterapias para el cáncer, ha anunciado la renuncia del Sr. Marc Lustig de su Junta Directiva. La renuncia es efectiva de inmediato. La empresa agradeció al Sr. Lustig por sus importantes contribuciones durante su mandato.
브리아셀 테라퓨틱스(BriaCell Therapeutics)는 암 면역요법을 전문으로 하는 임상 단계의 생명공학 회사로, 마크 루스티그(Marc Lustig) 이사가 이사회를 사임했다고 발표했습니다. 사임은 즉시 효력을 발생합니다. 회사는 루스티그 씨의 임기 동안의 중요한 기여에 감사를 표했습니다.
BriaCell Therapeutics, une entreprise de biotechnologie en phase clinique spécialisée dans les immunothérapies contre le cancer, a annoncé la démission de M. Marc Lustig de son conseil d'administration. La démission prend effet immédiatement. L'entreprise a exprimé sa gratitude pour les contributions significatives de M. Lustig durant son mandat.
BriaCell Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Immuntherapien gegen Krebs spezialisiert hat, hat den Rücktritt von Herrn Marc Lustig aus seinem Vorstand bekannt gegeben. Der Rücktritt tritt sofort in Kraft. Das Unternehmen drückte seine Dankbarkeit für die bedeutenden Beiträge von Herrn Lustig während seiner Amtszeit aus.
- None.
- Resignation of a board member, which may indicate potential instability or changes in strategic direction.
PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has accepted the resignation of Mr. Marc Lustig, MSc, MBA from the Board of Directors, effective immediately. The Board thanks Marc for his strong contributions to the Company over his tenure.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com
Investor Relations Contact:
CORE IR
investors@briacell.com
FAQ
What recent change has occurred in BriaCell's Board of Directors?
When did Mr. Marc Lustig resign from BriaCell's Board of Directors?
What is the stock symbol for BriaCell Therapeutics?
What did BriaCell say about Mr. Marc Lustig's resignation?
